FDA accepts NDA for Aricept Patch for Alzheimer’s disease (AD)

Eisai announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for Aricept Patch (donepezil transdermal system) for the treatment of mild, moderate and severe stages of Alzheimer’s disease (AD). The Aricept Patch is a weekly transdermal patch being developed to provide an alternative formulation for Alzheimer’s patients.

Aricept is a reversible acetylcholinesterase inhibitor presently approved for the treatment of all stages of AD. It is currently available in 5, 10, and 23mg tablets and 5 and 10mg orally disintegrating tablets.

For more information call (888) 422-4743 or visit www.aricept.com.